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Abstract Breast involvement by lymphoma is uncommon
and poses challenges in diagnosis. Lymphomas may clini-
cally, radiologically, and morphologically mimic both benign
and neoplastic conditions. We describe two cases of
lymphoid malignancies predominantly involving the breast,
both presenting diagnostic dilemmas. The first case, ALK-
negative anaplastic large-cell lymphoma involving a seroma
associated with a breast implant, is an emerging clinicopath-
ologic entity. Anaplastic large-cell lymphoma has been
identified in association with breast implants and seroma
formation relatively recently. The second case, hairy cell
leukemia involving the breast and ipsilateral axillary sentinel
lymph node, is, to our knowledge, the first reported case of
hairy cell leukemia involving the breast at the time of
diagnosis. While a localized bone lesion was present at time
of diagnosis, bone marrow involvement was relatively mild
in comparison to that seen in the breast and lymph node. In
the first case, lymphoma occurred in a clinical setting where
malignancy was unsuspected, highlighting the importance of
careful morphologic evaluation of paucicellular samples, as
well as awareness of rare clinicopathologic entities, in
avoiding a misdiagnosis of a benign inflammatory infiltrate.
In the second case, the lymphoid neoplasm exhibited classic
morphologic and immunophenotypic features, but presented
at an unusual site of involvement. Knowledge of the patient's
concurrent diagnosis of hairy cell leukemia involving the
bone marrow and bone helped avoid a misdiagnosis of
carcinoma rather than lymphoma.
Keywords Anaplasticlargecelllymphoma.Anaplastic
lymphomakinase.Breast.Breastimplant.
Hairycellleukemia.Primary breastlymphoma.
Seroma.T-cellneoplasm
Introduction
Lymphoid malignancies are the most frequent nonepithelial
neoplasms to involve the breast; however, they comprise
only a small percentage of all mammary malignancies [1].
Correspondingly, the breast is an unusual site of involve-
ment by lymphoma [2]. About half of all lymphoid
malignancies involving the breast represent primary tumors;
the remainder represents secondary breast involvement by a
systemic neoplasm [3–5]. Most primary breast lymphomas
are B-cell lymphomas; T-cell neoplasms are rare [1]. The
most common lymphoma is diffuse large B-cell lymphoma
followed by extranodal marginal zone lymphoma of
mucosa-associated lymphoid tissue (MALT lymphoma).
Less commonly seen are B-lymphoblastic lymphoma,
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otherwise specified, classical Hodgkin's lymphoma, and
follicular lymphoma [6, 7]. Secondary breast lymphomas
show a similar distribution, with increased frequency of
follicular lymphoma.
We describe two cases of rare lymphoid malignancies
arising in or predominantly involving the breast. The first
case of seroma-associated ALK-negative anaplastic large
cell lymphoma (ALCL) occurred in a clinical setting in
which malignancy was unsuspected. The second case of
hairy cell leukemia exhibited the classic morphologic and
immunophenotypic features of this entity, but involved a
highly unusual location.
Case histories
Case 1
The patient was a 54-year-old Caucasian woman with a
history of right breast carcinoma 17 years earlier, which
was treated with a right mastectomy; reconstruction
included bilateral silicone implants. The right silicone
implant was subsequently replaced by a saline implant,
and the patient remained well until 10 months before
presentation, when an ultrasound performed because of
gradual left breast enlargement revealed a peri-implant
fluid collection. The seroma was drained, and the left
silicone implant was replaced by a saline implant. At the
time of implant removal and replacement, the grossly
unremarkable implant capsule was examined histological-
ly and interpreted as a chronic inflammatory infiltrate with
fibrosis surrounding a pseudocystic space. Over the next
10 months, the seroma persisted despite intermittent
surgical drainage.
At the time of presentation, the seroma was again
aspirated, and the fluid specimen was submitted for
cytological evaluation. A diagnosis of lymphoma was
made, and this was followed by removal of the left saline
implant and excision of the surrounding fibrous capsule.
Review of the initial capsulectomy specimen from
10 months earlier revealed the presence of ALK-negative
ALCL. Staging evaluation by PET-CT revealed low-level
fluorodeoxyglucose (FDG) uptake within the left chest wall
muscle and skin overlying the left breast, consistent with
postoperative changes; no other sites of FDG avidity were
identified. A bone marrow biopsy was negative for
lymphoma. Ann Arbor stage was IA. The patient under-
went four cycles of chemotherapy with cyclophosphamide,
doxorubicin, vincristine, and prednisone (CHOP) followed
by involved-field radiation therapy (45 Gy). She is in
complete remission without evidence of lymphoma
7 months after diagnosis.
Case 2
The patient was a 45-year-old Caucasian woman with onset
of left hip and leg pain 2 months before presentation. CBC
showed mild anemia and a normal white blood cell count
with an absolute monocytopenia of 175 cells/μL. She was
treated initially with NSAIDs for presumed bursitis without
relief then was given a 1-week prednisone taper and the
pain completely resolved. A bone scan demonstrated three
areas of abnormal uptake in the left proximal femur, and
subsequent magnetic resonance imaging (MRI) confirmed
three discrete areas within the left femur consistent with a
marrow-infiltrating process. These findings were suggestive of
metastatic carcinoma and prompted further radiologic evalu-
ation. A mammogram showed an increased density in the
upper outer quadrant of the left breast compared with a study
3 years earlier. CT scans of the chest, abdomen, and pelvis
confirmed the left breast density and showed no splenomegaly
or lymphadenopathy. Breast MRI confirmed a 2.5 cm left
upper outer quadrant mass and also revealed a small area of
enhancement in the 10 o'clock position of the right breast.
A stereotactic biopsy of the left breast revealed ductal
carcinoma in situ (DCIS), while a subsequent core biopsy
of the left proximal femur showed involvement by hairy
cell leukemia. The patient then underwent a staging
posterior iliac crest bone marrow biopsy and aspirate,
which also showed involvement by hairy cell leukemia, and
left breast lumpectomy and left axillary sentinel lymph
node biopsy. The lumpectomy contained extensive DCIS,
as well as prominent atypical lymphoid infiltrates with
morphologic and immunohistochemical features of hairy
cell leukemia. The sentinel lymph node was negative for
metastatic carcinoma, but showed a massive atypical
lymphoid infiltrate, consistent with nodal involvement by
hairy cell leukemia. She was treated with a 7-day infusion
of cladribine for hairy cell leukemia. A repeat posterior iliac
crest bone marrow biopsy and aspirate performed posttreat-
ment showed minimal residual involvement by hairy cell
leukemia involving <1% of nucleated cells.
A right breast stereotactic biopsy was then performed
which revealed both invasive ductal carcinoma and DCIS.
The patient underwent bilateral simple mastectomies. The
left mastectomy contained residual DCIS with negative
margins, as well as sparse involvement by hairy cell
leukemia. The right mastectomy revealed both invasive
ductal carcinoma and DCIS with negative margins and no
evidence of involvement by hairy cell leukemia. A right
axillary sentinel node biopsy was positive for metastatic
carcinoma and negative for lymphoma. She underwent
completion axillary dissection on the right and an additional
12 lymph nodes were removed, all of which were negative
for carcinoma or lymphoma. After treatment with Lupron
and tamoxifen, she is in complete remission from her breast
238 J Hematopathol (2009) 2:237–244carcinoma and hairy cell leukemia 14 months after
diagnosis.
Materials and methods
Pathologic materials from both cases were submitted to our
institution in consultation. These included hematoxylin and
eosin (H&E)- and immunohistochemical-stained sections of
the initial capsulectomy and seroma fluid cell block, a Wright-
Giemsa-stained cytospin smear of the seroma fluid, and H&E-
stained sections of the second capsulectomy from case 1.
Multiple materials from case 2 were sent for review including:
H&E and immunohistochemical-stained sections of the left
proximal femur core biopsy, the left breast lumpectomy and
axillarysentinel lymphnode biopsy,andthe twoposterioriliac
crest bone marrow biopsies; Wright-Giemsa-stained smears of
the two bone marrow aspirates; reports of flow cytometric
analysis performed on the bone marrowspecimens; and H&E-
stained sections of the left simple mastectomy.
Formalin-fixed, paraffin-embedded tissues of the second
capsulectomy specimen from case 1, and the left simple
mastectomy from case 2 were available for additional
immunohistochemical and in situ hybridization studies. Two-
micronthicktissuesectionswereprepared,deparaffinized,and
rehydrated according to standard laboratory protocols. A
combination of ethylenediaminetetraacetic acid and boric acid
in Tris buffer (CC1 reagent, Ventana) was used for antigen
retrieval before primary antibody incubation. Immunohisto-
chemistry was performed using avidin-biotin peroxidase
complex with a peroxidase-labeled detection system on a
Benchmark XT automated immunostainer (Ventana Medical
Systems, Tucson, AZ) using validated staining protocols. In
situ hybridization for kappa and lambda immunoglobulin light
chains and EBV-encoded RNA (EBER) was performed using
HX Automatic System Benchmark (Ventana) according to the
manufacturer's instructions. Signals were detected using the
Alkaline Phosphatase Enhanced Detection Kit (Ventana).
Antibodies and probes studied in each case, their sources,
and the dilutions used are summarized in Table 1.
In case 1, DNA was isolated from paraffin-embedded
capsulectomy tissue using xylene followed by 100% ethanol
rinse; deparaffinized tissue was then processed with
QIAGEN QIAamp DNA micro Kits (QIAGEN, Valencia,
CA). T-cell clonality assays were performed using polymer-
ase chain reaction (PCR) according to the manufacturer's
instructions with Taq polymerase (AmpliTAQ Gold, Applied
Biosystems, Foster City, CA) and reagents purchased from
InVivoScribe Technologies LLC, San Diego, CA (TCRγ
Gene Clonality Assay for ABI Fluorescence Detection). The
kits used the primer sequences published by the BIOMED-2
[8] and products were analyzed by capillary gel electro-
phoresis (Applied Biosystems 3100xl, Foster City, CA).
All cytologic, histologic, immunohistochemical, and in
situ hybridization studies of both cases, as well as results of
molecular genetic studies in case 1 and flow cytometric
Antibody or probe Source Dilution Case(s)
studied
CD3 Ventana Medical Systems, Tuscon, AZ Prediluted 1, 2
CD4 Novocastra Laboratories, Newcastle Upon Tyne, UK 1:20 1
CD20 Ventana Medical Systems Prediluted 1, 2
CD30 Ventana Medical Systems Prediluted 1
CD43 Biogenex, CA 1:40 1
CD79a Ventana Medical Systems Prediluted 1
CD138 Serotec, Raleigh, NC 1:30 1
Mum1 Dako Corporation, Carpinteria, CA 1:20 1
Pax5 Ventana Medical Systems Prediluted 1
Granzyme B Chemicon International, Chemicon, CA 1:10 1
Perforin Lab Vision Products, Freemont, CA 1:20 1
ALK Ventana Medical Systems Prediluted 1
Kappa Ventana Medical Systems – 1
Lambda Ventana Medical Systems – 1
HHV-8 Advanced Biotechnologies, Columbia, MD 1:50 1
EBER INFORM EBER PROBE, Ventana Medical Systems – 1
DBA.44 Dako Corporation 1:10 2
Cytokeratin CAM5.2 Becton-Dickinson, San Jose, CA 1:80 2
Cytokeratin AE1/AE3 Signet Laboratories, Dedham, MA 1:160 2
CD45 Ventana Medical Systems Prediluted 2
Table 1 Antibodies and
probes used for immunohisto-
chemical analysis and in situ
hybridization
HHV-8 human herpes virus-8,
EBER Epstein-Barr virus RNA
J Hematopathol (2009) 2:237–244 239analysis in case 2, were reviewed by four of the authors.
Clinical data were obtained from medical records. The
Institutional Review Board of Partners HealthCare ap-
proved this study.
Results
Case 1
Microscopic examination of the first capsulectomy speci-
men demonstrated dense fibrous tissue containing a few
small scattered clusters of large atypical cells that were
partially necrotic and inconspicuous on low-power exam-
ination (Fig. 1a and inset). The majority of the lymphoid
infiltrate consisted of small lymphocytes, occasional histio-
cytes, and mature plasma cells. The cytospin preparation of
the aspirated seroma fluid demonstrated highly atypical
large cells (Fig. 1b), as did the second capsulectomy
specimen. In the latter, the tumor cells were more numerous
and viable with larger, multifocal aggregates than seen in
the prior capsulectomy (Fig. 1c, d). Both fibrous capsules
also contained refractile material consistent with silicone
particles (Fig. 1e)[ 9]. Immunohistochemical stains of the
Fig. 1 ALK-negative ALCL arising in a breast peri-implant capsule
and associated seroma. a Low-power examination of the initial
implant capsulectomy specimen reveals an apparent benign chronic
inflammatory infiltrate in a background of dense fibrosis (H&E, ×40);
however, atypical, but focally necrotic, large cells with hyperchro-
matic, irregular nuclei, and abundant eosinophilic cytoplasm are
visible on high magnification (inset,H & E ,× 4 0 0 ) .b Large
malignant-appearing cells with high nuclear-to-cytoplasmic ratios,
prominent nucleoli, vacuolated cytoplasm, and mitotic figures are
present in a cytospin of the seroma aspirate (Wright-Giemsa stain,
×1,000). c The second implant capsulectomy contains fibrosis, chronic
inflammation, and more conspicuous clusters of large, atypical cells
adjacent to the seroma cavity (H&E, ×100). d Viable clusters of large
infiltrating cells have pleomorphic nuclei and prominent nucleoli with
occasional “hallmark cells” present (H&E, ×400). e The implant
capsule contains focal deposits of refringent, nonpolarizable material
consistent with silicone adjacent to partially viable clusters of large
atypical cells (H&E, ×400). f–h Immunohistochemical staining
demonstrates the neoplastic cells to be positive for CD4 (f) and
CD30 (g), but negative for ALK-1 (h; ×400). i T-cell receptor PCR
identified a clonal rearrangement with Vγ10 primers (174.5 bp, blue
tracing), as well as an indeterminate peak with Vγ1-8 primers
(218.6 bp, green tracing), consistent with the presence of a clonal T-
cell population
240 J Hematopathol (2009) 2:237–244first capsulectomy and cell block specimens demonstrated
the large cells to be positive for CD30, CD4, and CD43,
and negative for ALK-1, CD2, CD3, CD5, CD7, CD8,
CD15, CD45, and cytokeratins AE1/AE3 and CAM5.2
(Fig. 1f–h). Additional immunohistochemical and in situ
hybridization studies performed on the second capsulec-
tomy specimen showed the tumor cells to be strongly
positive for Mum-1, and negative for CD20, CD79a, Pax5,
CD138, kappa and lambda immunoglobulin light chains,
HHV-8, and EBER. PCR demonstrated the presence of a
clonal rearrangement of the T-cell receptor gene with Vγ10
primers, as well as a peak of indeterminate relative height
with Vγ1-8 primers (Fig. 1i). Based on these morphologic,
immunohistochemical, and molecular genetic findings, a
diagnosis of ALK-negative ALCL was made on all three
specimens.
Case 2
Microscopic examination of the left femur core biopsy
revealed replacement of bone by a dense infiltrate of small
lymphoid cells with abundant pale cytoplasm. The posterior
iliac crest bone marrow biopsy showed a normocellular
marrow with trilineage hematopoiesis with an atypical
infiltrate of small to medium-sized lymphoid cells in a
patchy, interstitial distribution, comprising approximately
30% of the overall cellularity (Fig. 2a). The cells had oval
to spindle-shaped nuclei with dispersed chromatin and
abundant pale cytoplasm. On examination of the aspirate
smear, numerous characteristic hairy cells were identified
(Fig. 2a inset). Immunohistochemical stains of both the
femur and bone marrow specimens showed the lymphoid
cells to be positive for CD45, CD20, and DBA.44 and
negative for CD3 and cytokeratin AE1/AE3 (Fig. 2a). Flow
cytometry identified an abnormal lymphoid population
comprising 6% of all cells with increased light scatter and
expression of CD19, CD20, CD22, FMC-7, CD11c, CD25
(partial), CD103, and monotypic lambda immunoglobulin
light chain. The cells were negative for CD5, CD10, and
CD23. The morphologic and immunophenotypic findings
were diagnostic of hairy cell leukemia involving the bone
marrow and proximal femur.
Gross examination of the left breast lumpectomy
revealed two well-circumscribed, tan-white nodules mea-
suring 1.7 and 0.7 cm. On microscopic examination, the
nodules corresponded to dense stromal infiltrates of
monotonous small cells; extensive cribriform DCIS was
also present in these and adjacent areas (Fig. 2b–d). In areas
of low cellularity, the small cells were difficult to identify,
and had a cytomorphology and linear infiltrative pattern
reminiscent of the classic type of invasive lobular carcino-
ma [10]. In more cellular areas where the tumor cells
formed larger aggregates and sheets, the infiltrate resem-
bled the less common alveolar or solid types of invasive
lobular carcinoma [10, 11]. The left axillary sentinel node
was almost entirely replaced by sheets of similar-appearing
cells (Fig. 2e and inset). Immunohistochemical stains
revealed the atypical cells within the breast stroma and
lymph node to be positive for CD20 and DBA.44 and
negative for CD3 and cytokeratin AE1/AE3 (Fig. 2f).
Based on the morphologic and immunophenotypic find-
ings, and the presence of synchronous disease in the bone
and bone marrow, a diagnosis of hairy cell leukemia
involving the left breast and axillary sentinel lymph node
was made.
The posterior iliac crest bone marrow biopsy performed
after treatment with cladribine revealed a normocellular
marrow with maturing trilineage hematopoiesis; no atypical
lymphoid infiltrate was seen morphologically. However,
flow cytometric analysis revealed a small abnormal
population comprising <1% of all cells with expression of
CD19, CD20 (bright), CD11c, CD25, CD103, and mono-
typic lambda immunoglobulin light chain. The findings
were consistent with minimal residual bone marrow
involvement by hairy cell leukemia. The left simple
mastectomy showed foci of residual DCIS involving a
healing biopsy site. Also present in between both benign
and malignant ducts and lobules was a sparse infiltrate of
cells with oval nuclei and abundant pale cytoplasm
(Fig. 2g). Immunohistochemical stains showed these cells
to be positive for CD45, CD20, and DBA.44 and negative
for CD3 and cytokeratins AE1/AE3 and CAM5.2, consis-
tent with residual hairy cell leukemia (Fig. 2h, i). The
degree of breast involvement was markedly decreased
compared with the pretreatment lumpectomy specimen.
Discussion
Both cases of lymphoma involving the breast described
here represent rare lymphoma subtypes, and hence pre-
sented diagnostic challenges. The case of ALK-negative
ALCL occurred in a clinical setting in which malignancy
was not suspected, and the malignant cells were initially
overlooked. ALCL is characterized by the presence of large
cells with abundant cytoplasm and pleomorphic, often
horseshoe-shaped nuclei, termed “hallmark cells”, with
expression of CD30, and often loss of multiple pan-T-cell
antigens. The presence of the anaplastic lymphoma kinase
(ALK) gene translocation and expression of ALK protein
defines ALK-positive ALCL, which occurs in children and
young adults and has a relatively favorable prognosis, while
ALK-negative ALCL occurs in older individuals who often
present with advanced disease and has a worse outcome,
although better than that for peripheral T-cell lymphoma,
not otherwise specified [12–14]. ALK-negative ALCL
J Hematopathol (2009) 2:237–244 241should be distinguished from primary cutaneous ALCL,
which also lacks ALK, but which presents with localized
skin involvement and has a favorable prognosis [15].
As summarized by two recent studies, there have been
12 reported cases of ALCL arising as a primary breast
neoplasm in association with prosthetic silicone or saline
implants, ten of which were confirmed to be ALK-negative
[16, 17]. In the majority of these cases (8/12, 67%) the
presenting symptom was the formation of a peri-implant
seroma; the remaining patients presented with a mass or
ulceration [16–22]. ALK-negative ALCL has been identi-
fied after both cosmetic augmentation and reconstruction
following mastectomy for primary breast carcinomas. Most
affected patients have had a good prognosis with prolonged
disease-free survival despite negativity for ALK, leading
some investigators to suggest that this clinicopathologic
entity may be more closely related to the primary cutaneous
form of ALCL [17]. Indeed, prognosis in nonnodal ALCL
may be more closely related to site of presentation than to
ALK status [23].
Fig. 2 Hairy cell leukemia involving the bone marrow, breast, and
axillary sentinel lymph node. a A posterior iliac crest bone marrow
aspirate smear contains medium-sized lymphoid cells with oval nuclei,
dispersed chromatin, and abundant pale cytoplasm with circumferen-
tial cytoplasmic projections (inset, Wright-Giemsa, ×1,000). CD20
stain of the core biopsy highlights the interstitial pattern of marrow
involvement characteristic of hairy cell leukemia (×100). b–d Left
breast lumpectomy containing prominent monomorphic infiltrates of
small discohesive cells with abundant pale cytoplasm and round to
oval nuclei present singly and in linear strands surrounding benign
lobules (b; H&E, ×200), as larger clusters and aggregates surrounded
by thin bands of fibrous stroma (c; H&E, ×400), as well as in solid
sheets (d; H&E, ×400). DCIS was present elsewhere (not shown).
e The sentinel lymph node shows massive replacement of the
paracortex and hilum by cells with abundant pale eosinophilic
cytoplasm and oval to spindled nuclei, morphologically similar to
those in the breast (inset, H&E, ×400); residual primary follicles are
present at the periphery of the node (H&E, ×20). f Immunohisto-
chemistry of the breast specimen reveals infiltrating cells to be CD20-
positive (inset) and strongly DBA.44-positive (×400). g Subsequent
mastectomy demonstrates an infiltrate of monomorphic cells present
singly and in loose linear arrays adjacent to residual cribriform DCIS
(H&E, ×400). h–i A cytokeratin cocktail immunostain (h) of the
mastectomy specimen highlights DCIS, but not the infiltrating cells,
which are positive for CD20 (i; ×400)
242 J Hematopathol (2009) 2:237–244Although breast implants do not appear to increase the
risk of subsequent development of breast carcinoma [24],
there may be an etiologic association between prolonged
exposure to silicone from breast implants and the rare
development of ALK-negative ALCL [16–18, 25]. There is
speculation that exposure to silicone, due to microscopic
leaks from silicone-filled implants or from saline-filled
implants containing silicone-impregnated capsules, drives
an immunologic reaction that leads to T-cell activation,
clonal expansion, and the eventual development of lym-
phoma [16–18, 26].
The diagnosis in this case was challenging for several
reasons. At the time of the first silicone implant removal
and replacement, malignancy was not suspected. Not only
was the patient in complete remission from her breast
cancer, but there existed at that time only isolated case
reports in the literature of the association between ALK-
negative ALCL, breast implant capsules, and seroma
formation [18, 19, 21, 22], so there was little awareness
of this diagnostic entity. On morphological examination,
the initial capsulectomy specimen was sparsely cellular,
with only rare partially degenerated atypical cells. The
diagnosis of ALK-negative ALCL was rendered on an
aspirate of the seroma fluid that was sent for cytologic
evaluation in which cellular detail was well-preserved,
leading to the identification of frankly malignant nuclear
features and review of the previous specimen. The second
capsulectomy specimen showed more extensive involve-
ment by lymphoma with greater tumor cell viability and
more conspicuous “hallmark cells”. This case highlights the
importance of careful morphologic evaluation of paucicel-
lular or degenerated samples, even in instances where the
clinical suspicion for malignancy is low. It also illustrates
the importance of maintaining an awareness of emerging
diagnostic entities associated with specific clinical and
pathological settings, even those that occur with low
frequency.
The case of hairy cell leukemia exhibited classic
morphologic and immunophenotypic features of this entity
[27], but the diagnosis was challenging because of the
unusual clinical presentation in the breast. The clinical
symptom of leg pain, in combination with the radiological
findings of masses in both the breasts and femur, was more
suggestive of metastatic breast carcinoma than a hemato-
logic malignancy. The initial core biopsy of the breast
showing DCIS reinforced this clinical suspicion. In this
context, the morphological differential diagnosis of a breast
tumor composed of small discohesive cells with abundant
cytoplasm included invasive lobular carcinoma [10, 11].
The relatively small nuclear size and minimal cytological
atypia were subtle clues to the lymphoid, rather than
epithelial, nature of the cells. Importantly, knowledge of
the patient's concurrent diagnosis of hairy cell leukemia
involving the femur and bone marrow led to the perfor-
mance of an appropriate panel of immunohistochemical
stains and confirmation of the diagnosis.
Hairy cell leukemia typically involves bone marrow and
spleen but may also involve other sites including the central
nervous system, gastrointestinal and urogenital tracts, heart,
lungs, skeletal muscle, skin, thymus, and thyroid [28–32].
Breast involvement, either at the time of diagnosis or later
in the disease course, has not been reported to our
knowledge. Since breast tissue is rarely sampled at the
time of autopsy, the breast may be an under-recognized site
of involvement in established disease. Lymph node and
skeletal involvement have been reported in hairy cell
leukemia and typically occur at an advanced stage of
disease [27, 33]. Therefore, a striking feature in this case is
the prominent degree of breast and axillary sentinel lymph
node involvement and involvement of a localized bone
lesion at the time of diagnosis, in the absence of extensive
bone marrow involvement or splenomegaly.
In summary, we report two unusual cases of lymphoma
involving the breast that presented diagnostic challenges. In
the case of seroma-associated ALK-negative ALCL, the
presence of malignancy was unsuspected clinically and was
initially overlooked, but the clinical findings of a long-
standing breast implant complicated by recurrent peri-
implant seroma formation fit the clinical profile of an
emerging diagnostic entity, and repeat cytologic evaluation
with an appropriate panel of immunohistochemical stains
led to the correct diagnosis. In the case of hairy cell
leukemia, the patient presented with clinical findings
suggestive of metastatic carcinoma rather than lymphoma.
Careful attention to the concomitant diagnosis of hairy cell
leukemia involving other sites helped to avoid a misdiag-
nosis of invasive carcinoma. Both cases illustrate the
importance of performing a careful and thorough clinical
and pathological evaluation when considering a diagnosis
of a rare lymphoma subtype involving the breast.
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